title: [The change of serum vascular endothelial growth factor and matrix metalloproteinases-9 in proliferative hemangioma treated with propranolol].
abstract: OBJECTIVE
  To study the level of serum vascular endothelial growth factor, matrix metalloproteinases-9 in the proliferative hemangioma before and after propranolol treatment.
  
  
  METHODS
  The serum VEGF, MMP-9 was detected with ELISA assay before treatment and after 4 weeks and 8 weeks of propranolol treatment. The relationship between the serum VEGF, MMP-9 and the prognosis was analyzed.
  
  
  RESULTS
  The serum VEGF (295.4 +/- 158.1) pg/ml was high before treatment, then decreased after 4 weeks and 8 weeks of treatment (255.7 +/- 130.4) pg/ml, (224.2 +/- 120.6) pg/ml. The serum VEGF was significantly lower after 8 weeks of treatment (P < 0.05). The serum MMP-9 was also decreased after treatment, showing a positive relationship with VEGF.
  
  
  CONCLUSIONS
  Propranolol can treat the proliferative hemangioma through decreasing the serum VEGF and MMP-9.
authors.affiliation: Department of Plastic and Burn Surgery, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
authors.forename: Zhong-Fang
authors.initials: ZF
authors.lastname: Zhao
authors.forename: Ren-Rong
authors.initials: RR
authors.lastname: Lü
authors.forename: Ran
authors.initials: R
authors.lastname: Huo
authors.forename: Hong-Bing
authors.initials: HB
authors.lastname: Fu
authors.forename: Guang-Qi
authors.initials: GQ
authors.lastname: Xu
mesh_terms: D005260:Female; D006391:Hemangioma / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007223:Infant; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000097:blood*; D011433:Propranolol / Q000627:therapeutic use*; D044967:Serum / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
chemical_list: C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D011433:Propranolol; D020780:Matrix Metalloproteinase 9